SCHEMBL5724404

SCHEMBL5724404

CNC(=O)c1csc(N2CCC(O[Si](C)(C)C(C)(C)C)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.47
OGA O60502 3/20 0.45
SCD O00767 1/20 0.42
ACKR3 P25106 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724678 0.87 HRH3 (0.47) HRH3OGASCD
SCHEMBL5724102 0.86 HRH3 (0.60) HRH3OGASCDL3MBTL1
SCHEMBL5724480 0.84 HRH3 (0.45) HRH3OGASCDL3MBTL1
SCHEMBL5724249 0.83 OGA (0.48) HRH3OGASCDL3MBTL1
SCHEMBL5723678 0.80 HRH3 (0.46) HRH3OGASCDACKR3
SCHEMBL5723738 0.80 OGA (0.49) HRH3OGAACKR3L3MBTL1
SCHEMBL5723961 0.74 OGA (0.45) HRH3OGAACKR3L3MBTL1
SCHEMBL5724047 0.74 RAB9A (0.44) HRH3SCDL3MBTL1
SCHEMBL5723906 0.72 OGA (0.38) OGASCDL3MBTL1
SCHEMBL5724259 0.72 OGA (0.41) HRH3OGAACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD HRH3 3678/4885OGA 3469/4885SCD 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.